Allovectin-7 therapy in metastatic melanoma

Agop Y. Bedikian(The University of Texas MD Anderson Cancer Center), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori)

Expert Opinion on Biological Therapy

May 14, 2008

10.1517/14712598.8.6.839

Cited by 37

Related Papers

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

|New England Journal of Medicine|2017|2.2k

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

|The Lancet Oncology|2017|780

Interleukin-12: Biological Properties and Clinical Application

|Clinical Cancer Research|2007|606

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

|The Lancet Oncology|2020|530

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

|The Lancet Oncology|2017|501